Comparing the risk of hepatitis B virus reactivation between direct‐acting antiviral therapies and interferon‐based therapies for hepatitis C
Kawagishi, N., Suda, G., Onozawa, M., Kimura, M., Maehara, O., Ohara, M., Izumi, T., Umemura, M., Ito, J., Nakai, M., Sho, T., Natsuizaka, M., Morikawa, K., Ogawa, K., Sakamoto, N.
Published in Journal of viral hepatitis (01.12.2017)
Published in Journal of viral hepatitis (01.12.2017)
Get full text
Journal Article
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib
Rimini, M., Kudo, M., Tada, T., Shigeo, S., Kang, W., Suda, G., Jefremow, A., Burgio, V., Iavarone, M., Tortora, R., Marra, F., Lonardi, S., Tamburini, E., Piscaglia, F., Masi, G., Cabibbo, G., Foschi, F.G., Silletta, M., Kumada, T., Iwamoto, H., Aoki, T., Goh, M.J., Sakamoto, N., Siebler, J., Hiraoka, A., Niizeki, T., Ueshima, K., Sho, T., Atsukawa, M., Hirooka, M., Tsuji, K., Ishikawa, T., Takaguchi, K., Kariyama, K., Itobayashi, E., Tajiri, K., Shimada, N., Shibata, H., Ochi, H., Yasuda, S., Toyoda, H., Fukunishi, S., Ohama, H., Kawata, K., Tani, J., Nakamura, S., Nouso, K., Tsutsui, A., Nagano, T., Takaaki, T., Itokawa, N., Okubo, T., Arai, T., Imai, M., Joko, K., Koizumi, Y., Hiasa, Y., Cucchetti, A., Ratti, F., Aldrighetti, L., Cascinu, S., Casadei-Gardini, A.
Published in ESMO open (01.12.2021)
Published in ESMO open (01.12.2021)
Get full text
Journal Article
Prevalence and risk factors of hepatitis B virus reactivation in interferon-free direct-acting antiviral therapies for hepatitis C
Kawagishi, N, Suda, G, Onozawa, M, Kimura, M, Maehara, O, Ohara, M, Izumi, T, Umemura, M, Ito, J, Nakai, M, Sho, T, Natsuizka, M, Morikawa, K, Ogawa, K, Sakamoto, N
Published in Journal of hepatology (2017)
Published in Journal of hepatology (2017)
Get full text
Journal Article
1035 HEAT SHOCK FACTOR 1 ACCELERATES HEPATOCELLULAR CARCINOMA DEVELOPMENT BY ACTIVATING NUCLEAR FACTOR κB/MITOGEN-ACTIVATED PROTEIN KINASE
Chuma, M, Sakamoto, N, Hige, S, Nakanishi, M, Natsuizaka, M, Suda, G, Sho, T, Maeda, S
Published in Journal of hepatology (01.04.2013)
Published in Journal of hepatology (01.04.2013)
Get full text
Journal Article
661 COMPARISON OF HCV-ASSOCIATED GENE EXPRESSION AND CELL SIGNALING PATHWAYS IN CELLS WITH OR WITHOUT HCV REPLICON AND IN REPLICON-CURED CELLS
Nishimura-Sakurai, Y, Sakamoto, N, Mogushi, K, Nagaie, S, Nakagawa, M, Itsui, Y, Tasaka-Fujita, M, Onuki-Karakama, Y, Suda, G, Mishima, K, Yamamoto, M, Ueyama, M, Funaoka, Y, Watanabe, T, Azuma, S, Sekine-Osajima, Y, Kakinuma, S, Enomoto, N, Tanaka, H, Watanabe, M
Published in Journal of hepatology (2010)
Published in Journal of hepatology (2010)
Get full text
Journal Article
165P BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Amadeo, E., Persano, M., Tada, T., Suda, G., Shimose, S., Kudo, M., Yoo, C., Rossari, F., Vitiello, F., Casadei Gardini, A., Rimini, M.
Published in Annals of oncology (01.11.2023)
Published in Annals of oncology (01.11.2023)
Get full text
Journal Article
FRI-406 - Changes in liver steatosis and lipid metabolism accompanied by successful interferon-free DAAs therapy in HCV infected patients; a comprehensive analysis
Kawagishi, N., Suda, G., Morikawa, K., Ogawa, K., Sakamoto, N.
Published in Journal of hepatology (01.04.2018)
Published in Journal of hepatology (01.04.2018)
Get full text
Journal Article
185P The combined role of patients (pts) gender and disease etiology on unresectable HCC (uHCC) first-line (1L) treatment outcome
Cesario, S., Genovesi, V., Rimini, M., Tada, T., Suda, G., Shimose, S., Kudo, M., Finkelmeier, F., Yoo, C., Presa, J., Iavarone, M.A., Marra, F., Foschi, F.G., Tamburini, E., Lonardi, S., Piscaglia, F., Salani, F., Vivaldi, C., Gardini, A. Casadei, Masi, G.
Published in Annals of oncology (01.06.2024)
Published in Annals of oncology (01.06.2024)
Get full text
Journal Article
184P Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients (P) progressed to atezolizumab plus bevacizumab (AB)
Persano, M., Rimini, M., Foti, S., Camera, S., Rossari, F., Amadeo, E., Vitiello, F., Tada, T., Suda, G., Shimose, S., Kudo, M., Yoo, C., Cheon, J., Finkelmeier, F., Lim, H.Y., Presa, J., Mascia, L., Cascinu, S., Scartozzi, M., Gardini, A. Casadei
Published in Annals of oncology (01.06.2024)
Published in Annals of oncology (01.06.2024)
Get full text
Journal Article
170P Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Vitiello, F., Rimini, M., Persano, M., Suda, G., Shimose, S., Finkelmeier, F., Masi, G., Rossari, F., Amadeo, E., Casadei Gardini, A., Tada, T., Kudo, M., Cheon, J., Lim, H.Y., Yoo, C.
Published in Annals of oncology (01.11.2023)
Published in Annals of oncology (01.11.2023)
Get full text
Journal Article
154P Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Persano, M., Rimini, M., Tada, T., Suda, G., Shimose, S., Kudo, M., Yoo, C., Cheon, J., Finkelmeier, F., Lim, H.Y., Presa, J., Masi, G., Bergamo, F., Iavarone, M.A., Cabibbo, G., Foschi, F.G., Piscaglia, F., Cascinu, S., Scartozzi, M., Casadei Gardini, A.
Published in Annals of oncology (01.11.2023)
Published in Annals of oncology (01.11.2023)
Get full text
Journal Article
173P Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Persano, M., Rimini, M., Tada, T., Suda, G., Shimose, S., Kudo, M., Yoo, C., Cheon, J., Finkelmeier, F., Lim, H.Y., Presa, J., Masi, G., Bergamo, F., Iavarone, M.A., Cabibbo, G., Foschi, F.G., Piscaglia, F., Cascinu, S., Scartozzi, M., Casadei Gardini, A.
Published in Annals of oncology (01.11.2023)
Published in Annals of oncology (01.11.2023)
Get full text
Journal Article
188P Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Rimini, M., Amadeo, E., Vitiello, F., Foti, S., Persano, M., Tada, T., Suda, G., Shimose, S., Kudo, M., Cheon, J., Finkelmeier, F., Lim, H.Y., Piscaglia, F., Masi, G., Yoo, C., Lonardi, S., Rossari, F., Camera, S., Casadei Gardini, A., Presa, J.
Published in Annals of oncology (01.11.2023)
Published in Annals of oncology (01.11.2023)
Get full text
Journal Article
972P Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Persano, M., Rimini, M., Tada, T., Suda, G., Shimose, S., Kudo, M., Cheon, J., Finkelmeier, F., Presa, J., Masi, G., Yoo, C., Lonardi, S., Piscaglia, F., iavarone, M.A., TAMBURINI, E., Cabibbo, G., Silletta, M., Cascinu, S., Scartozzi, M., Casadei Gardini, A.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
PD-15 Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments
Persano, M., Rimini, M., Toshifumi, T., Suda, G., Shigeo, S., Kudo, M., Cheon, J., Finkelmeier, F., Presa, J., Masi, G., Yoo, C., Lonardi, S., Tovoli, F., Piscaglia, F., Iavarone, M., Marra, F., Tamburini, E., Cabibbo, G., Scartozzi, M., Casadei-Gardini, A.
Published in Annals of oncology (01.06.2023)
Published in Annals of oncology (01.06.2023)
Get full text
Journal Article
84P Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population
Rimini, M., Casadei-Gardini, A., Tada, T., Suda, G., Shimose, S., Kudo, M., Cheon, J., Finkelmeier, F., Lim, H.Y., Rimassa, L., Presa, J., Masi, G., Yoo, C., Lonardi, S., Tovoli, F., Cascinu, S., Cucchetti, A.
Published in Annals of oncology (01.11.2022)
Published in Annals of oncology (01.11.2022)
Get full text
Journal Article
SO-14 Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study
Rimini, M., Rimassa, L., Kudo, M., Shigeo, S., Toshifumi, T., Suda, G., Yoo, C., Cheon, J., Lonardi, S., Scartozzi, M., Tamburini, E., Masi, G., Cascinu, S., Casadei-Gardini, A.
Published in Annals of oncology (01.06.2022)
Published in Annals of oncology (01.06.2022)
Get full text
Journal Article
P-171 Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet REFLECT trial inclusion criteria
Sho, T., Suda, G., Ogawa, K., Kitagataya, T., Yamada, R., Shigesawa, T., Suzuki, K., Nakamura, A., Nakai, M., Natsuizaka, M., Morikawa, K., Sakamoto, N.
Published in Annals of oncology (01.07.2020)
Published in Annals of oncology (01.07.2020)
Get full text
Journal Article